Ambrx Biopharma Quarterly Income Statements Chart
Quarterly
|
Annual
Ambrx Biopharma Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|
| revenues | 1,123,000 | 24,000 | |
| operating expenses: | |||
| research and development | 14,393,000 | 9,750,000 | |
| general and administrative | 5,900,000 | 6,306,000 | |
| impairment of intangible assets | |||
| total operating expenses | 20,293,000 | 16,056,000 | |
| income from operations | -19,170,000 | -16,032,000 | |
| yoy | |||
| qoq | 19.57% | ||
| operating margin % | |||
| other income, net: | |||
| investment income | 1,428,000 | 551,000 | |
| interest income | 211,000 | 190,000 | |
| other income | 10,000 | 62,000 | |
| total other income | 1,649,000 | 803,000 | |
| income before income taxes | -17,521,000 | -15,229,000 | |
| benefit from income taxes | -305,000 | -73,000 | |
| net income | -17,826,000 | -15,302,000 | |
| yoy | |||
| qoq | 16.49% | ||
| net income margin % | |||
| net income per share | -0.05 | -0.05 | |
| weighted-average ordinary shares used to compute net income per share—basic and diluted | 391,283,214 | ||
| other comprehensive loss, net of tax: | |||
| other comprehensive income, net of tax: | |||
| changes in comprehensive income before reclassifications | -13 | -26 | |
| amounts reclassified from accumulated other comprehensive loss | 36 | 352 | |
| total other comprehensive income | 23 | 326 | |
| comprehensive loss | -17,803 | -14,976 | |
| weighted-average ordinary shares used to compute net income per share —basic and diluted | 314,969,897 |
We provide you with 20 years income statements for Ambrx Biopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ambrx Biopharma stock. Explore the full financial landscape of Ambrx Biopharma stock with our expertly curated income statements.
The information provided in this report about Ambrx Biopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.